Other C-MYC repressors, such as the BET (Bromodomain and Extra-Terminal Domain) inhibitor JQ1, have shown good results in different cancer types, and could be tested in SCLC patients that express high C-MYC levels [52,53]. Here, MYC is linked to cancer.